绝经后激素治疗与乳腺癌风险：现状与未解问题。
Postmenopausal hormone therapy and breast cancer risk: current status and unanswered questions.
机构信息
Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
出版信息
Endocrinol Metab Clin North Am. 2011 Sep;40(3):509-18, viii. doi: 10.1016/j.ecl.2011.05.006. Epub 2011 Jul 12.
Abstract
Many women take hormone therapy (HT) for menopausal symptom relief. Studies have tried to clarify whether various factors can modify the risk of HT, such as the age at initiation, dose, duration, or type of HT, or characteristics of the individual, such as family history or body mass index. The relative risks of breast cancer associated with HT across various subgroups of women should be considered similar, but absolute risks can vary significantly among women and this may inform individual decision making. For breast cancer survivors, systemic HT should be discouraged.
摘要
许多女性采用激素疗法（HT）缓解更年期症状。研究试图阐明各种因素是否可以改变 HT 的风险，例如起始年龄、剂量、持续时间或 HT 类型，或个体特征，如家族史或体重指数。应认为与 HT 相关的乳腺癌的相对风险在女性的各种亚组中相似，但绝对风险在女性中差异很大，这可能会影响个人决策。对于乳腺癌幸存者，应不鼓励使用全身 HT。
相似文献
1
Postmenopausal hormone therapy and breast cancer risk: current status and unanswered questions.
Endocrinol Metab Clin North Am. 2011 Sep;40(3):509-18, viii. doi: 10.1016/j.ecl.2011.05.006. Epub 2011 Jul 12.
2
Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States).
Cancer Causes Control. 2006 Jun;17(5):695-703. doi: 10.1007/s10552-005-0001-7.
3
How to judge the association of postmenopausal hormone therapy and the risk of breast cancer.
Front Med China. 2010 Sep;4(3):290-3. doi: 10.1007/s11684-010-0093-7. Epub 2010 Aug 5.
4
Postmenopausal hormone therapy and risk of breast cancer.
Chang Gung Med J. 2009 Mar-Apr;32(2):140-7.
5
Long-term hormone therapy for perimenopausal and postmenopausal women.
Cochrane Database Syst Rev. 2017 Jan 17;1(1):CD004143. doi: 10.1002/14651858.CD004143.pub5.
6
Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use.
J Clin Oncol. 2010 Aug 20;28(24):3830-7. doi: 10.1200/JCO.2009.26.4770. Epub 2010 Jul 19.
7
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.
Endocr Pract. 2017 Jul;23(7):869-880. doi: 10.4158/EP171828.PS.
8
Different menopausal hormone regimens and risk of breast cancer.
Ann Oncol. 2018 Aug 1;29(8):1771-1776. doi: 10.1093/annonc/mdy212.
9
Menopausal hormone therapies: their effect on mammographic density and breast cancer risk.
Gynecol Endocrinol. 2005 Jul;21 Suppl 1:12-6. doi: 10.1080/09513590400030046.
10
Mechanisms underlying social inequality in post-menopausal breast cancer.
Dan Med J. 2014 Oct;61(10):B4922.
引用本文的文献
1
Development of a Breast Cancer Risk Prediction Model Incorporating Polygenic Risk Scores and Nongenetic Risk Factors for Korean Women.
Cancer Epidemiol Biomarkers Prev. 2023 Sep 1;32(9):1182-1189. doi: 10.1158/1055-9965.EPI-23-0064.
2
Identification of the Active Ingredient and Beneficial Effects of Fruits on Menopausal Symptoms in Ovariectomized Rats.
Biomolecules. 2021 Jul 16;11(7):1033. doi: 10.3390/biom11071033.
3
Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study.
Breast Cancer Res. 2015 Mar 31;17(1):49. doi: 10.1186/s13058-015-0563-6.
4
IPAD: the Integrated Pathway Analysis Database for Systematic Enrichment Analysis.
BMC Bioinformatics. 2012;13 Suppl 15(Suppl 15):S7. doi: 10.1186/1471-2105-13-S15-S7. Epub 2012 Sep 11.
5
The soy isoflavone genistein inhibits the reduction in Achilles tendon collagen content induced by ovariectomy in rats.
Scand J Med Sci Sports. 2012 Oct;22(5):e108-14. doi: 10.1111/j.1600-0838.2012.01516.x. Epub 2012 Aug 1.
本文引用的文献
1
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.
JAMA. 2010 Oct 20;304(15):1684-92. doi: 10.1001/jama.2010.1500.
2
Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use.
J Clin Oncol. 2010 Aug 20;28(24):3830-7. doi: 10.1200/JCO.2009.26.4770. Epub 2010 Jul 19.
3
Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy.
J Clin Oncol. 2010 Jun 1;28(16):2690-7. doi: 10.1200/JCO.2009.24.8799. Epub 2010 May 3.
4
Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society.
Menopause. 2010 Mar;17(2):242-55. doi: 10.1097/gme.0b013e3181d0f6b9.
5
Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial.
J Clin Oncol. 2009 Dec 20;27(36):6135-43. doi: 10.1200/JCO.2008.21.7166. Epub 2009 Nov 9.
6
Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?
J Clin Oncol. 2009 Nov 1;27(31):5138-43. doi: 10.1200/JCO.2008.21.6432. Epub 2009 Sep 14.
7
Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS).
J Cardiovasc Transl Res. 2009 Sep;2(3):228-39. doi: 10.1007/s12265-009-9104-y. Epub 2009 May 22.
8
Hormone replacement therapy, family history, and breast cancer risk among postmenopausal women.
Epidemiology. 2009 Sep;20(5):752-6. doi: 10.1097/EDE.0b013e3181a71279.
9
Breast cancer after use of estrogen plus progestin in postmenopausal women.
N Engl J Med. 2009 Feb 5;360(6):573-87. doi: 10.1056/NEJMoa0807684.
10
Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.
Lancet Oncol. 2009 Feb;10(2):135-46. doi: 10.1016/S1470-2045(08)70341-3. Epub 2009 Jan 23.
Zotero 插件